Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-1 Inhibitor Firsekibart Combined with Needle-Knife Arthroscopy in Gouty Knee Arthritis
ChiCTR2600127190Phase 4Not yet recruiting
- Sponsor
- Hunan University of Medicine General Hospital
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of genakumab in gout, sponsored by Hunan University of Medicine General Hospital. Primary endpoints: SF-36 Quality of Life Score at week 24 and Lysholm Knee Function Score at week 24. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
genakumab
03
Conditions
gout
Beyond the preview
Go deeper on ChiCTR2600127190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127190.